Flovent (Asthma) - Forecast and Market Analysis to 2023
GlobalData has released its new PharmaPoint Drug Evaluation report, “Flovent (Asthma) - Forecast and Market Analysis to 2023”. The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.
Originally approved by the Food and Drug Administration (FDA) in 1996, GSK’s Flovent (fluticasone propionate) is a synthetic ICS therapy with potent anti-inflammatory activity. It is used for the maintenance treatment of asthma prophylactically in children and adults. Flovent is now available in two formulations, Diskus and HFA, which received the FDA approval in 2000 and 2004, respectively. Flovent’s active ingredient, fluticasone propionate, can bind to glucocorticoid receptors with high affinity and inhibit the secretion of mediators involved in asthma, such as histamine, eicosanoids, leukotrienes, and cytokines. It is three times more potent than budenoside, and two times more potent than the active metabolite of beclomethasone dipropionate.
Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on Flovent including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for Flovent for the top eight countries from 2013 to 2023.
Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.
Reasons to buy
Understand and capitalize by identifying products that are most likely to ensure a robust return
Stay ahead of the competition by understanding the changing competitive landscape for Asthma
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
Make more informed business decisions from insightful and in-depth analysis of Flovent performance
Obtain sales forecast for Flovent from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia)
Sales for Flovent in the Asthma Market
Flovent sales are expected to decrease from $895million in 2013 to $236 million in 2023 with anegative Compound Annual Growth Rate (CAGR)of 12.5%.
Major growth drivers for Flovent in the Asthmamarket over the forecast period include:
Flovent, like all ICSs, is a gold standard ofasthma therapy and is of central importance insecuring asthma control in patients withpersistent disease.
Flovent has been used since the 1990s andhas a well-known long-term safety profile.
Flovent is available in two formulations: ametered-dose inhaler (MDI) version and aDiskus version.
The corticosteroid ingredient in Flovent(fluticasone) is more potent than Pulmicort’s(budenoside).Conversely, major barriers to the growth of Floventin the Asthma market include:
Twice-daily administration makes Flovent lessconvenient to use than Asmanex Twisthaler(mometasone furoate) or leukotriene modifiers(Singulair).
Many physicians consider all ICSs roughlyequally potent, despite the fact that Flovent isactually more potent.
The high price of Flovent makes it lessdesirable than its generic counterparts inincreasingly cost-conscious society.